Objectives While diabetes has been linked to several cancers in the gastrointestinal (GI) tract, findings have been mixed for sites other than colorectal and liver cancer. We used the Women's Health Initiative (WHI) data and conducted a comprehensive assessment of associations between diabetes and GI malignancy (esophagus, stomach, liver, biliary, pancreas, colon, and rectal).
developing many types of cancer [2, 3] . Hyperinsulinemia acting through aberrations in the insulin-like growth factor pathways and steroid hormone metabolism, but also through independent mitogenic actions, is the main mechanism suggested to explain the association between diabetes and cancer [4] . Several gastrointestinal tract (GI) cancers have been linked to diabetes, including colorectal cancer [5, 6] , pancreatic cancer [7] , and liver cancer [8, 9] ; however, a major question is whether diabetes independently increases risk of these cancers, or whether the diseases simply share common risk factors, as many studies have not thoroughly accounted for potential confounders [10] . How risk of these cancer types is influenced by diabetes severity, diabetes treatment, or the duration of diabetes has not been thoroughly investigated.
The association of diabetes with other sites of cancer in the GI tract also is unclear. Studies on the association of diabetes with biliary tract cancer have been mixed. Three have shown an excess risk of biliary cancer in patients with diabetes [11] [12] [13] ; one was a register-based study, which was unable to adjust for most potential confounders [11] , and two were composed mainly of men [12, 13] . Another two studies examining diabetes did not observe an association with biliary cancer [14, 15] . Similarly, the relationship between diabetes and esophageal or gastric cancer has not been established [13, 14] .
In this large prospective study using data from the Women's Health Initiative (WHI) [16] , we conducted a comprehensive assessment of the association between diabetes and risk of primary GI malignancies, including esophageal, stomach, liver, biliary tract, pancreas, colon, and rectal cancer. Our analyses included detailed information on potential confounders, treatment status, and duration of diabetes, and relied on central coding of all cases.
Materials and methods

Women's Health Initiative
The WHI was designed to address major causes of morbidity and mortality in postmenopausal women [16] and included both clinical trials (CT) and an observational study (OS) . Details of the scientific rationale, eligibility requirements, and baseline characteristics of the participants in the WHI have been published elsewhere [17] [18] [19] [20] [21] . Briefly, a total of 161,808 women aged 50-79 were recruited at 40 clinical centers throughout the United States between 1 September 1993 and 31 December 1998. The WHI CT includes four overlapping components: two Hormone Therapy Trials (27,347 women), a Dietary Modification Trial (48,835 women), and a Calcium/ Vitamin D Supplementation Trial (36,282 women) . Participants in the OS included 93,676 women who were screened for the CT but proved to be ineligible or unwilling to participate or were recruited through a direct invitation for the OS. The study was overseen by ethics committees at all 40 clinical centers and at the coordinating center, as well as by a data and safety monitoring board. All participants in the WHI gave informed consent and were followed prospectively.
The following participants were excluded from the original cohort of 161,808 for this analysis: 14,849 women who had a history of cancer (except non-melanoma skin cancer) at baseline; 783 women who had no follow-up time; 217 women who were diagnosed with diabetes below age 20 or who were ever hospitalized for diabetic coma were considered to have type 1 diabetes; and 194 women who had missing values of the main exposures (including diabetes, age of diabetes onset, and diabetes treatment). Our findings are based on the remaining 145,765 women who comprised our study cohort (Fig. 1) .
Measurement of exposures, confounders, and outcomes
Diabetes
Diabetes at enrollment (prevalent diabetes) was defined as a positive answer to a question ''did a doctor ever say that you had sugar diabetes or high blood sugar when you were not pregnant?'' Gestational diabetes was not included in our study. Treated diabetes (yes, no) at enrollment was defined as whether the participant reported ever being treated for diabetes with pills or insulin shots. Diabetes was further categorized as no diabetes, diabetes-not treated with medication, diabetes-treated with oral medications only, and diabetes-treated with insulin (either alone or in combination with oral medications). The duration of diabetes at enrollment was calculated as the difference between age when first diagnosed with diabetes and age at enrollment.
Incident diabetes was also determined during the study follow-up period based upon a positive response regarding newly prescribed treatment for diabetes with pills or insulin shots on either the semi-annual or annual WHI follow-up questionnaires. Diagnosis of diabetes based on participant self-report was previously evaluated and deemed reliable. A validation study using a randomly selected sample of baseline specimens from the entire WHI population has shown that fasting glucose levels [126 mg/dl were seen in 3.4 % of 5,884 women without self-reported diabetes. In the clinical trials, 79 % of women who self-reported treated diabetes at baseline had a diabetes medication in the baseline medication inventory. The corresponding figure for the observational study was 77 % [22] . In addition, a recent validation study using 715 medical record reviews confirmed 92 % of self-reported prevalent diabetes and 82 % of self-reported incident diabetes. Evidence of diabetes was found in only 5 % of women who did not report diabetes [23] .
Confounders
The potential confounders considered in multivariable analyses included age at enrollment (\55, 55-59, 60-64, 65-69, 70-74, C75), ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black or African-American, Hispanic/Latino, non-Hispanic white, and other), education (high school or less, some college/technical training, college or some postcollege, and master's degree or higher), smoking status (never, pack-years ever smoked: \10, 10-\20, 20-\30, 30-\40, 40-\50, 50 or more),), body mass index (\18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, [=40), waist-to-hip ratio (quintile), physical activity as (metabolic equivalent tasks [METs] per week: \5, 5-\10, 10-\20, 20-\30, 30 or more), alcohol intake (non-drinker, past drinker, \1 drink per month, 1 drink/ month-\1 drink/week, 1-\7 drinks/week, 7 ? drinks/ week), total daily energy intake (quintile), percent of daily dietary calories from fat (quintile), history of hormone therapy use (none, estrogen alone, estrogen and progestin, mixed), and non-steroidal anti-inflammatory drugs use (NSAID) (yes, no). In order to be included in the medication inventory at baseline, the NSAID had to be used at least once a week and used for at least the last 2 weeks at the time of data collection. Additional risk factors were adjusted for specific individual cancers, including whether women ever had liver disease for liver cancer, gallstone disease for biliary cancer; stomach or duodenal ulcer disease as a Helicobacter pylori surrogate in the gastric cancer model, and red meat (quintile) and folate intake (quintile) for colon cancer.
Follow-up and ascertainment of cases
Initial cancer reports were ascertained by self-administered questionnaires (every 6 months in the CT through 2005, and annually in the CT after 2005 and in OS), with all cases subsequently confirmed by medical record review. All GI cancer cases were then coded centrally in accordance with the Surveillance Epidemiology and End Results (SEER) coding guidelines. For these analyses, participants were followed to first cancer diagnosis of interest, date of death, loss to follow-up (including non-participation in the extension of WHI after 2005), or 14 August 2009, whichever occurred first. The completion rate of annual questionnaires was 93-96 % through 2005. Among all living participants, the participant rate to the extension was about 73 %.
Statistical analysis
We evaluated baseline differences in sociodemographic and clinical characteristics according to diabetes status using a chi-square test for categorical variables and a t test for continuous variables. Cox proportional hazards regression models were employed to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) in age-adjusted and multivariable-adjusted models. In the multivariable models, we adjusted for potential confounders as described above with and without adding obesity indices (BMI and waist-to-hip ratio). Different study cohorts (participation in OS or each CT, and different treatment assignments for each CT) were treated as strata in the model in order to take into account possible different baseline hazards in different sub-groups and any potential treatment effects.
The effect of exposure was examined employing different metrics. Our primary analysis was an evaluation of the effect of diabetes at time of study enrollment (prevalent diabetes), including its duration and treatment, on risk of individual GI cancers. In a secondary analysis, we considered all diabetes as an exposure, including incident diabetes newly occurring during WHI follow-up. In the analysis including both prevalent and incident diabetes, a time-dependent covariate in a Cox proportional hazards regression model was generated by taking account of changes in diabetes status during follow-up. The effect of treatment status was compared by entering multiplicative interaction terms in the models to compare untreated and treated diabetes, as well as treatment with oral agents only and treatment with insulin. Further, we compared diabetes treatment with metformin and non-metformin drugs. The effect of diabetes duration was compared by entering Cancer Causes Control (2013) 24:577-585 579 multiplicative interaction terms in the models to compare both categories (\10 vs. [10 years) and continuous years of duration. The proportionality assumption was satisfied for all exposure variables of interest and potential confounding variables based on graphs of scaled Schoenfeld residuals [24] . All statistical analyses were conducted using SAS (Version 9.2, SAS Institute, Cary, NC.)
Results
Baseline characteristics by diabetes status at enrollment are shown in Table 1 . Compared to women with no diabetes, women with diabetes were significantly more likely to be older and have higher BMI, waist-to-hip ratio, physical inactivity, total daily energy intake, percent daily dietary calories from fat, and use of NSAIDS; and were significantly less likely to be white (non-Hispanic), have graduated from college, currently drink, ever have smoked, and have history of estrogen and progestin use. Women with diabetes were significantly less likely to report a family history of cancer and more likely to report a personal history of gallstones, liver disease, and stomach or duodenal ulcer. Among the 8,154 diabetic women, about 24.6 % were receiving no diabetic pharmacologic treatment, 47.8 % were using oral medications only, and 27.6 % were receiving insulin (Table 1) . Overall, 12.7 % were using metformin. Women with a self-reported diabetes diagnosis at enrollment had significantly increased age-adjusted risk of liver, pancreatic, colon, and rectal cancer, but risk of esophageal or stomach cancer was not significantly different from non-diabetic women. Although diabetes was also associated with excess biliary tract cancer risk, the HR did not reach significance. The magnitudes of risk in multivariable models were slightly attenuated from those in age-adjusted models, especially when models with further adjusted for BMI and waist-to-hip ratio. However, overall results for each type of GI cancer remained consistent (Table 2) . Further, we assessed whether the effects of diabetes on risk of GI cancer differed by obesity status and did not detect significant interaction effect for any type of GI cancer (data not shown). When the analysis was limited to women with treated diabetes at baseline, the point estimates of risk were higher for liver, pancreas, and rectal cancer. Similar results were obtained when considering incident treated diabetes diagnosed during follow-up (data not shown).
When the analyses were stratified by type of diabetes treatment (Table 3) , only colon cancer was significantly associated with both treated and untreated diabetes, while liver, pancreas, and rectal cancer were significantly associated only with treated diabetes. When diabetes treatment was separated into metformin or non-metformin treatment, only pancreatic cancer was significantly associated with metformin treatment, while all listed cancers were significantly associated with diabetes with non-metformin treatment. However, due to limited sample sizes, none of these treatment type differences was statistically significant, as can be seen from the overlapping confidence intervals. Similarly, diabetes of longer duration also had somewhat stronger links to liver, pancreatic, and rectal cancer (Table 4) . Although the differences were not statistically significant between shorter and longer durations when modeled as a categorical variable, the differences were statistically significant in the models in which duration of diabetes was included as a continuous variable for pancreatic cancer (HR 1.03 per year of diabetes duration; 95 % CI, 1.01-1.06, p = 0.002) and rectal cancer (1.04, 95 % CI, 1.01-1.07, p = 0.006) (data not shown). Unfortunately, given the very small number of esophageal and stomach cancer cases, we were unable to similarly evaluate the effects of diabetes treatment and duration on disease risk.
In order to address questions about reverse causation, we performed sensitivity analyses excluding cases that occurred in the first 2 years of follow-up for both liver and pancreatic cancer. The results were similar to what we presented for the primary analyses (data not shown).
Discussion
In this large prospective study of postmenopausal women followed for *10 years, diabetes mellitus was significantly associated with an increased risk of liver, pancreatic, colon, and rectal cancers. In particular, women with treated diabetes or longer duration of diabetes appeared to have greater risk of liver, pancreatic, and rectal cancer. Although relatively few women were treated with metformin, it was significantly associated with increased pancreatic risk. However, we cannot evaluate the associations for other GI cancer sites (i.e., biliary, esophagus, and stomach) due to lack of statistical power.
Accumulating experimental and epidemiological evidence suggests that hyperinsulinemia may be the underlying mechanism to explain the association between diabetes and cancer. Insulin could be directly related to risk by promoting tumor proliferation. It could also affect risk by modulating circulating levels of growth factors and their binding proteins or by competing with their specific receptors in target tissues [25] . Insulin binds to and activates the IGF-I receptor [4,] . Thus, reduced insulin sensitivity with compensatory hyperinsulinemia leads to stimulation of cell proliferation and could act as a growth stimulus in preneoplastic and neoplastic cells. Excess insulin could also reduce the level of IGF-BP1 with resultant increases in the levels of circulating free, bioactive IGF-I.
Previous observational studies have also reported that diabetes is associated with an increased risk of liver, pancreatic, and colorectal cancer [2, [5] [6] [7] [8] , though questions remain about the validity of these observed relationships. One concern is that the association between diabetes and cancer risk may simply reflect common underlying risk factors (e.g., excess body weight, diet, and/or lack of physical activity). Moreover, few studies were able to adjust for important confounding factors such as waist circumference or waist-to-hip ratio, a better measure of visceral fat than BMI [10] . In our study, adjustment for BMI or adiposity did not materially alter the diabetescancer relations observed indicating that confounding by adiposity is unlikely to account for these associations. However, our study was unable to adjust for Hepatitis B virus infection (HBV) and Hepatitis C virus infection (HCV), two important risks of liver cancer. However, in order for confounding to account for the magnitude of increase in risk that we observed, there would have to be much stronger association of hepatitis B or C and diabetes that is known to be present [26] . Thus, our observed association between diabetes and liver cancer is unlikely to be explained by confounding by HBV and HCV infection.
Another concern is that some of the observed associations may be due to early chronic disease that may influence glucose homeostasis. For example, the diabetes-liver cancer association may be due to reverse causality. End stage liver disease itself can cause glucose intolerance and overt diabetes [27] , and diabetes has been associated with a spectrum of liver disease [28, 29] , ranging from non- , alcohol intake (non-drinker, past drinker, \1 drink per month, 1 drink/month-\1 drink/week, 1-\7 drinks/week, 7 ? drinks/ week), total daily energy intake (quintile), percent of daily dietary calories from fat (quintile), history of hormone therapy use (none, estrogen alone, estrogen and progestin, mixed), and non-steroidal anti-inflammatory drugs use (yes, no). In addition, we adjusted for an additional variable (whether women ever had stomach or duodenal ulcer disease) for stomach cancer; an additional variable (whether women ever had liver disease) for liver cancer; gallstone disease for biliary cancer, red meat (quintile) and folate intake (quintile) for colon cancer c In the models of this column (model 3), we further adjusted for body mass index (\18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, C40), waist-to-hip ratio (quintile) besides all covariates in model 2 In each multivariable model, we adjusted for age (\55, 55-59, 60-64, 65-69, 70-74, C75), ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black or African-American, Hispanic/Latino, non-Hispanic white, and other), education (high school or less, some college/ technical training, college or some postcollege, and master's degree or higher), smoking status (never, pack-years ever smoked: \10, 10-\20, 20-\30, 30-\40, 40-\50, 50 or more)), body mass index (\18.5, 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, C40), waist-to-hip ratio (quintile), physical activity (metabolic equivalent tasks [METs] per week: \5, 5-\10, 10-\20, 20-\30, 30 or more), alcohol intake (nondrinker, past drinker, \1 drink per month, 1 drink/month-\1 drink/week, 1-\7 drinks/week, 7 ? drinks/week), total daily energy intake (quintile), percent of daily dietary calories from fat (quintile), history of hormone therapy use (none, estrogen alone, estrogen and progestin, mixed), and non-steroidal anti-inflammatory drugs use (yes, no). In addition, we adjusted for an additional variable (whether women ever had stomach or duodenal ulcer disease) for stomach cancer; an additional variable (whether women ever had liver disease) for liver cancer; gallstone disease for biliary cancer, red meat (quintile) and folate intake (quintile) for colon cancer
The significance of bold is at 0.05 level alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and cirrhosis, which enhance susceptibility to liver cancer [30] [31] [32] . Although it is difficult to establish clearly that diabetes indeed preceded any underlying chronic liver disease in our cohort, the findings of the diabetes-liver cancer relationship were not materially altered when the analysis was further adjusted for selfreported liver disease at baseline. In addition, another risk factor for liver cancer, HCV, may itself cause diabetes. Similarly, abnormal glucose metabolism due to pancreatic cancer may also explain the apparent diabetes-pancreatic cancer association observed by us and others. However, a positive association between diabetes and pancreatic cancer risk has been found when restricted to diabetes that precedes the diagnosis of pancreatic cancer by at least 5 years [33] . We also did a sensitivity analysis excluding the first 2 years of follow-up for both liver and pancreatic cancer and found similar results to the primary analyses. In addition, our finding of an increased risk associated with diabetes 10 years or more years suggests that reverse causation is unlikely to explain the association. Whether diabetes is associated with biliary tract cancer is controversial. An elevated risk of biliary tract cancer has been suggested in some [11] [12] [13] 34] , but not all studies [14, 15, 35] . Our study noted a significant increase in biliary tract cancer risk only among diabetic women who were treated with non-metformin drug therapy. The relationship between diabetes and esophageal or gastric cancer is also uncertain [13, 14] . There was a significantly decreased risk of esophageal cancer among men reported in one study [13] , and a significantly increased risk of gastric cancer among women reported in another study [14] . However, as in our study, the majority of studies did not find an association for either cancer, perhaps due to the small number of cases [34, 35] .
Our data suggest that diabetes requiring pharmacologic treatment had stronger links to liver, pancreatic, and rectal cancer, but not to colon cancer. Diabetes requiring pharmacologic treatment may be a proxy for more severe or longer duration diabetes, which may further increase cancer risk. Our data did not show the risk of any GI cancer to differ between type 2 diabetes patients receiving insulin and oral medication only, but suggested that longer duration of diabetes may increase the risk of liver, pancreatic, and rectal cancer. Since longer duration of diabetes is correlated with the need for pharmacologic treatment, the independent role of these is not clear. Type 2 diabetes patients begin to require insulin therapy when there is a significant decline in endogenous insulin production. Similarly, insulin is more commonly prescribed in patients with a longer duration of type 2 diabetes and is used more often in those with one or more comorbid conditions that preclude the use of oral medications [2] . In addition, once type 2 diabetes mellitus patients become insulin dependent, patient are treated with different analogues of insulin that may have different pharmacokinetic and pharmacodynamic profiles [36] . For example, studies observed that patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin [37, 38] . This was suggested by our analyses stratified treatment into metformin and non-metformin treatment. An increased risk of GI cancer was noted in patients with non-metformin treatment but not in patients with metformin treatment with an exception for pancreatic cancer. However, due to the small number of women in the metformin drug use group, power limits our ability to draw firm conclusions. Strengths of our study include the prospective design, detailed information on exposure, central coding of cancer diagnoses, and information on potential confounders, including data on waist circumference and waist-to-hip ratio. However, there are some study limitations as well. Our results pertain to postmenopausal women who were generally well educated, although the cohort is relatively diverse both geographically and racially. Diabetes status relied on self-report, and no medical records were obtained for review. Thus, there is some degree of misclassification in both our diabetes and non-diabetes groups [22, 23] , which may make our estimates more conservative. Further, it is possible that a few participants might have had diabetes type 1 rather than type 2. However, a validation study in the WHI has shown a high concordance of self-report with a gold standard based on medical record review and with medication inventories [22, 23] . In addition, our measure of diabetes duration is likely an underestimate, since women could have had undiagnosed diabetes for an unknown length of time. Further, the power for examining the association of diabetes with several rare cancers is low, as is power for examining the treatment and duration of diabetes for all cancers other than colon, and for addressing association of specific type of anti-diabetes drugs with specific cancer sites.
In conclusion, in postmenopausal women, type 2 diabetes is associated with a significantly increased risk of cancers of the liver and pancreas, as well as colon and rectal cancer. The suggestion that diabetes severity, assessed by need for pharmacologic therapy and longer duration of diagnosis, further increases risk of pancreatic, liver, and rectal cancer requires further study.
